Free Trial

PetIQ Q4 2022 Earnings Report

PetIQ EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

PetIQ Revenue Results

Actual Revenue
$184.08 million
Expected Revenue
$191.80 million
Beat/Miss
Missed by -$7.72 million
YoY Revenue Growth
N/A

PetIQ Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

PetIQ Earnings Headlines

PetIQ Acquired by Bansk Group, Delisted from Nasdaq
PetIQ announces completion of acquisition by Bansk Group
Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
PetIQ Merges with Bansk Group in $1.5B Deal
See More PetIQ Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PetIQ? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetIQ and other key companies, straight to your email.

About PetIQ

PetIQ (NASDAQ:PETQ) operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

View PetIQ Profile

More Earnings Resources from MarketBeat

Upcoming Earnings